Peter E Barker

Summary

Affiliation: National Institute of Standards and Technology
Country: USA

Publications

  1. ncbi Measurement reproducibility in the early stages of biomarker development
    Walter S Liggett
    Statistical Engineering Division and Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Dis Markers 20:295-307. 2004
  2. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
  3. ncbi Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells
    Xiugong Gao
    Section of Molecular Biology, Department of Biology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    BMC Cell Biol 8:17. 2007
  4. ncbi Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST)
    Peter E Barker
    NIST NCI Biomarkers Validation Laboratory, DNA Technologies Group, Biotechnology Division, NIST, Gaithersburg, Maryland 20899 8311, USA
    Ann N Y Acad Sci 983:142-50. 2003
  5. ncbi Inter-rater agreement on chromosome 5 breakage in FISH-based mutagen sensitivity assays (MSAs)
    Peter E Barker
    DNA Technologies Group, Biotechnology Division, Chemical Sciences and Technology Laboratory, NIST NCI Biomarkers Validation Project, National Institute of Standards and Technology NIST, Gaithersburg, MD 20899 8311, USA
    Mutat Res 562:133-42. 2004
  6. ncbi Preparation and characterization of candidate reference materials for telomerase assays
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Clin Chem 51:1443-50. 2005
  7. ncbi Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19,
    Peter E Barker
    NIST-National Cancer Institute Cancer Biomarker Reference Laboratory, NIST Mass Spectrometry Data Center, Analytical Chemistry Division, NIST, Gaithersburg, MD 20899-8311, USA
    Clin Chem 52:1669-74. 2006
  8. ncbi Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection
    Yan Xiao
    NIST NCI EDRN Cancer Biomarker Reference Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
    Int J Cancer 122:2178-86. 2008
  9. ncbi Mitochondrial DNA as a cancer biomarker
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, 100 Bureau Dr, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 7:258-67. 2005
  10. ncbi Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells
    John P Jakupciak
    NIST, Biotechnology Division, 100 Bureau Drive, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 6:157-65. 2004

Detail Information

Publications20

  1. ncbi Measurement reproducibility in the early stages of biomarker development
    Walter S Liggett
    Statistical Engineering Division and Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Dis Markers 20:295-307. 2004
    ..As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker...
  2. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
    ..The detection of mtDNA mutations in body fluids using resequencing microarrays, which are more sensitive than other sequencing methods, could provide a strategy to measure mutation loads in remote anatomical sites...
  3. ncbi Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells
    Xiugong Gao
    Section of Molecular Biology, Department of Biology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    BMC Cell Biol 8:17. 2007
    ..We suggest that the influence of roxithromycin on SM-induced inflammatory reaction could play an important therapeutic role in the cytotoxicity exerted by this toxicant...
  4. ncbi Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST)
    Peter E Barker
    NIST NCI Biomarkers Validation Laboratory, DNA Technologies Group, Biotechnology Division, NIST, Gaithersburg, Maryland 20899 8311, USA
    Ann N Y Acad Sci 983:142-50. 2003
    ..Here we conceptualize the validation steps of cancer test development and examine how NIST activities impact health care through institutional focus on measurement, technology, and standards development programs...
  5. ncbi Inter-rater agreement on chromosome 5 breakage in FISH-based mutagen sensitivity assays (MSAs)
    Peter E Barker
    DNA Technologies Group, Biotechnology Division, Chemical Sciences and Technology Laboratory, NIST NCI Biomarkers Validation Project, National Institute of Standards and Technology NIST, Gaithersburg, MD 20899 8311, USA
    Mutat Res 562:133-42. 2004
    ..These results aid in estimating the components of assay variance due to definitions, technical parameters and biological variables...
  6. ncbi Preparation and characterization of candidate reference materials for telomerase assays
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Clin Chem 51:1443-50. 2005
    ..CONCLUSIONS: We have prepared and characterized a candidate reference material that appears to be suitable for use in a wide range of assays of telomerase activity and expression...
  7. ncbi Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19,
    Peter E Barker
    NIST-National Cancer Institute Cancer Biomarker Reference Laboratory, NIST Mass Spectrometry Data Center, Analytical Chemistry Division, NIST, Gaithersburg, MD 20899-8311, USA
    Clin Chem 52:1669-74. 2006
    ..This report summarizes the discussion and recommendations for proteomics reference materials...
  8. ncbi Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection
    Yan Xiao
    NIST NCI EDRN Cancer Biomarker Reference Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
    Int J Cancer 122:2178-86. 2008
    ....
  9. ncbi Mitochondrial DNA as a cancer biomarker
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, 100 Bureau Dr, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 7:258-67. 2005
    ..Hence, incomplete mitochondrial genome sequencing, designed to scan discrete portions of the genome, misses potentially important sequence variants associated with cancer or other diseases...
  10. ncbi Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells
    John P Jakupciak
    NIST, Biotechnology Division, 100 Bureau Drive, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 6:157-65. 2004
    ..Using this combination of telomerase activity and hTERT mRNA measurements, the automated system improved efficiency over traditional TRAP/PCR methods...
  11. ncbi Measurement of DNA biomarkers for the safety of tissue-engineered medical products, using artificial skin as a model
    Henry Rodriguez
    Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Tissue Eng 10:1332-45. 2004
    ..More importantly, this exploratory work addresses technological considerations that need to be addressed in order to expedite accurate and useful international reference standards for the emerging tissue-engineering industry...
  12. ncbi Semiconductor nanocrystal probes for human metaphase chromosomes
    Yan Xiao
    GeoCenters, Inc. and DNA Technologies Group, National Institute of Standards and Technology, Gaithersburg, MD 20899-8311, USA
    Nucleic Acids Res 32:e28. 2004
    ..Thus, semiconductor nanocrystal fluorophores offer a more stable and quantitative mode of fluorescence in situ hybridization (FISH) for research and clinical applications...
  13. ncbi Biomarkers used to detect genetic damage in tissue engineered skin
    Peter E Barker
    DNA Technologies Group, Chemical Science and Technology Laboratory, National Institute of Standards and Technology, 100 Bureau Drive, Mail Stop 831, Gaithersburg, MD 20899-8311, USA
    Adv Exp Med Biol 534:137-45. 2003
  14. ncbi Oxidative DNA damage biomarkers used in tissue engineered skin
    Henry Rodriguez
    DNA Technologies Group, Chemical Science and Technology Laboratory, National Institute of Standards and Technology, 100 Bureau Drive, Mail Stop 831, Gaithersburg, MD 20899-8311, USA
    Adv Exp Med Biol 534:129-35. 2003
  15. ncbi Quantitative infrared spectroscopy of formalin-fixed, paraffin-embedded tissue specimens: paraffin wax removal with organic solvents
    Curtis W Meuse
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, MD 20899 8313, USA
    Appl Immunohistochem Mol Morphol 17:547-52. 2009
    ..More importantly, these results establish a starting point from which further analysis of preanalytical processing methods can proceed...
  16. ncbi Nanotechnology: Emerging Developments and Early Detection of Cancer. A two-day workshop sponsored by the National Cancer Institute and the National Institute of Standards and Technology, August 30-31 2001, on the National Institute of Standards and Techno
    Steven J Zullo
    Chemistry and Life Sciences Division, Advanced Technology Program, National Institute of Standards and Technology, Gaithersburg, MD 20899-4730, USA
    Dis Markers 18:153-8. 2002
    ....
  17. ncbi NIST physical standards for DNA-based medical testing
    Peter E Barker
    NCI-NIST Biomarkers Validation Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899-8311, USA
    J Clin Lab Anal 16:5-10. 2002
    ..Here we summarize the NIST experience and programs for development of national standards for DNA-based medical diagnostic testing...
  18. ncbi Semiconductor nanocrystal conjugates, FISH and pH
    Yan Xiao
    Nat Methods 2:723. 2005
  19. ncbi Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:4545-9. 2007
    ....
  20. ncbi Validation of novel optical imaging technologies: the pathologists' view
    Wendy A Wells
    Dartmouth Medical School, Department of Pathology, 1 Rope Ferry Road, Hanover, New Hampshire 03755, USA
    J Biomed Opt 12:051801. 2007
    ....